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Predicting drug-induced liver injury in a preclinical setting remains challenging, as cultured
primary human hepatocytes (PHHs), pluripotent stem cell-derived hepatocyte-like cells
(HLCs), and hepatoma cells exhibit poor drug biotransformation capacity. We here
demonstrate that hepatic functionality depends more on cellular metabolism and extracellular
nutrients than on developmental regulators. Specifically, we demonstrate that increasing
extracellular amino acids beyond the nutritional need of HLCs and HepG2 cells induces
glucose independence, mitochondrial function, and the acquisition of a transcriptional profile
that is closer to PHHs. Moreover, we show that these high levels of amino acids are sufficient
to drive HLC and HepG2 drug biotransformation and liver-toxin sensitivity to levels similar to
those in PHHs. In conclusion, we provide data indicating that extracellular nutrient levels
represent a major determinant of cellular maturity and can be utilized to guide stem cell
differentiation to the hepatic lineage.
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Despite robust preclinical rodent studies, unpredicted livertoxicity remains one of the major reasons for drug fail-ure1. Hepatocytes express a set of highly specific cyto-
chrome P450 (CYP450) biotransforming enzymes that convert
many drugs to inactive or hepatotoxic compounds. As these
CYP450 enzymes differ significantly between species, drug bio-
transformation and hepatotoxicity can only be evaluated in
freshly isolated primary human hepatocytes (PHHs)2. However,
differences between donors necessitate the screening of multiple
PHH batches and rapid loss of hepatic function in two-
dimensional (2D) culture does not allow for PHH expansion
nor long-term drug exposure studies3,4. As a result, novel systems
are being developed to better maintain PHH function for an
extended time5–7. Alternative assays utilize hepatic cell lines such
as the HepG2 (ref. 8) and HepaRG models9, or transiently
immortalized PHHs10. Nevertheless, as these models still do not
reach drug biotransformation capacities of fresh PHHs, the major
goal of toxicologists remains the generation of expandable models
with stable CYP450 activity levels close to those of fresh
PHH11,12.
Hepatocytes derived from pluripotent stem cells (PSCs)
represent a highly versatile model13. PSCs are genetically normal
and can be expanded almost indefinitely. In addition, induced
PSC (iPSC) technology allows for the generation of models from
individuals with different susceptibility profiles14. PSCs have been
differentiated to cells that secrete albumin, store glycogen, and are
susceptible to infection with hepatotropic viruses15,16. However,
these cells are not mature and have therefore been termed
“hepatocyte-like cells” (HLCs). HLCs differ from PHHs at the
transcriptional, proteomic, and epigenetical level, and specifically
express low levels of hepatic transcription factors (TFs) and
CYP450 enzymes4,17,18. Recent studies have shown that utilizing
signals from the in vivo microenvironment can improve HLC
maturation. These approaches include co-culture with non-
parenchymal liver cells, micro-patterning on fibroblasts, and
adapting the culture system to three-dimensional-hydrogel or
even perfused systems, often combined with overexpression
of TFs to further boost functionality. Nevertheless, HLCs still
cannot predict hepatotoxicity at clinically relevant drug
concentrations19–23.
In recent years, cellular metabolism has emerged as an
important regulator of PSC fate24,25. Yet, even if single metabo-
lites were found to drive PSC differentiation to the neural line-
age26,27, the impact of nutrients on hepatic differentiation and
function remains unknown28. We here demonstrate that the
immature profile of HLCs is in fact determined by an immature
metabolic profile. We also show that extracellular amino acids
(AAs) represent a tool to drive both metabolic maturation and
the expression of CYP450 enzymes, and this in both HLCs and
HepG2 hepatoma cells. Finally, by adapting the model to a high-
throughput toxicity screening system, we demonstrate that AAs
drive hepatic differentiation to levels that allow detection of
hepatotoxins at clinically relevant concentrations.
Results
PSC differentiation yields immature hepatic progeny. To
evaluate and improve HLC function, we first compared hepatic
progeny of the human H9 embryonic stem cell line to cryopre-
served PHHs. As expected, during differentiation from PSC,
expression of pluripotency-associated genes decreased from day 0
onwards, whereas endoderm-associated genes were transiently
induced (Supplementary Fig. 1A). By day 20, hepatic transcripts,
such as alpha1-antitrypsin (AAT) and Na+ -taurocholate cotran-
sporting polypeptide (NTCP), reached levels found in PHHs
(Fig. 1a). Immunostaining and flow cytometry demonstrated that
more than 90% of HLCs stained positive for NTCP, hepatocyte
nuclear factor (HNF)4A and AAT (Fig. 1b and Supplementary
Fig. 1B). However, in line with other protocols17, expression
(Fig. 1c) and activity (Fig. 1d) of mature genes such as albumin
(ALB) or CYP3A4, the most important drug-biotransforming
enzyme, remained lower than in PHHs or even 12 h plated PHHs
(PHH 12 h). Consistently, the transcriptome of generated HLCs
clustered together with published protocols, at a distance of PHHs
(Fig. 1e). To gain molecular insights into the low CYP450
expression of HLCs, we used a weighted correlation network
analysis (WGCNA)29 to identify two gene clusters of transcrip-
tional regulators that differ between HLCs and PHHs. As pre-
viously described4,17, one of these contained genes involved in the
development and cytoskeleton. Surprisingly, CYP450 genes were
found to be co-regulated with metabolic rather than develop-
mental genes (Fig. 1f). When we assessed the trait relation between
the different clusters (Fig. 1g), we found a strong correlation
between modules containing CYP450 genes and genes involved in
gluconeogenesis, mitochondrial metabolism, AA metabolism, and
β-oxidation. As a lower correlation was found with modules
linked to development, polarity, and cytoskeleton, we hypothe-
sized that an immature metabolism is the prime reason for low
CYP450 expression.
PSCs are glycolytic whereas hepatocytes represent the main
gluconeogenic cell type. However, during hepatic differentiation,
transcript levels of the glycolytic genes hexokinase II (HKII) and
pyruvate kinase (PK)M2 remained high, whereas the gluconeogenic
genes (glucose 6 phosphatase (G6PC), fructose-bisphosphatase 1
(FBP1), phosphoenolpyruvate carboxykinase (PEPCK)) and the
liver-specific PKL isoform were not induced (Supplementary
Fig. 1C). This glycolytic phenotype was confirmed by a continued
high rate of glucose uptake (Fig. 1h). In accordance, measurements
of oxygen consumption rates (OCRs) confirmed a very low basal
mitochondrial activity, but not maximal respiratory capacity
(measured through addition of carbonyl cyanide-4-(trifluoro-
methoxy) phenylhydrazone (FCCP)) when comparing HLC D20
with PHH 12 h (Fig. 1i). As also demonstrated by others7, PHHs
quickly lose their mature features such ALB and CYP3A4
expression upon culturing (Supplementary Fig. 1D, E). Interest-
ingly, we also observed a switch from a gluconeogenic to a glycolytic
gene expression profile (Supplementary Fig. 1E), a switch from
glucose secretion to consumption (Fig. 1h), and reduction in basal
OCR and maximal reserve capacity in PHHs cultured for 72 h
(PHH 72 h) (Fig. 1i). This demonstrates that dedifferentiating
PHHs and HLCs display an immature metabolism and minimal
expression of drug-biotransforming genes.
Transcription factors regulate hepatic metabolism and func-
tion. The RNA-sequencing (RNAseq) studies, confirmed by
quantitative reverse-transcription PCR (qRT-PCR) (Supplemen-
tary Fig. 2A), also identified a number of hepatic TFs to be less
expressed in HLC D20 compared with PHHs. As overexpression
of hepatic TFs has been shown to enhance CYP450 activity to
some extent23,30, we next assessed whether these might also
rewire hepatic metabolism. We therefore utilized recombinase-
mediated cassette exchange (RMCE)31 to generate PSCs con-
taining a doxycycline-inducible cassette for the overexpression of
HNF1A, forkhead box (FOX)A3 and Prospero homeobox protein
(PROX1) (termed HC3X). Correct integration of all cassettes was
validated using PCR and fluorescence-activated cell sorting
(Supplementary Fig. 2B, C). As a control, we recombined tandem
dimer tomato (tdT) and demonstrated that ±100% of the cells
were tdT positive following doxycycline addition (Supplementary
Fig. 2D).
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Induction of HNF1A, FOXA3, and PROX1 from D4 until D20
induced their expression to levels near those of PHHs (Fig. 2a)
and increased both ALB and CYP3A4 mRNA. Transcript levels of
ALB now reached those of PHH 12 h and CYP3A4 expression was
increased 50-fold (Fig. 2a). Although albumin secretion by HC3X
D20 was found to be equal to PHH 12 h, the metabolization rate
of the probe compound 7-benzyloxy-4-trifluoromethylcoumarin
(BFC) was still very low (Fig. 2b). Overexpression was associated
with partial metabolic maturation. Transcripts for glycolytic
enzymes were decreased in HC3X D20, whereas expression of
G6PC and PEPCK were modestly increased (Supplementary
Fig. 2E). Interestingly, in contrast to HLC D20, HC3X D20 were
able to survive in the absence of glucose (Fig. 2c). In accordance,
glucose consumption and lactate secretion were reduced, whereas
pyruvate uptake was increased (Fig. 2d). However, no glucose
secretion (Fig. 2d) or increased OCR (Fig. 2e) was observed.
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Fig. 1 HLCs and PHHs cultured in 2D are functionally and metabolically immature. a Expression of AAT and NTCP in PHHs and differentiating HLCs. N=
3 independent differentiations, N= 4 donors for PHHs. Significance was compared with PHHs by unpaired two-tailed Student’s t-test. b Representative
immunofluorescence images of two independent differentiations with OCT4 staining on D0 and HNF4A/NTCP staining on D20. Scale bar represents
100 µm. c Expression of ALB and CYP3A4 in PHHs and differentiating HLCs. N= 3 independent differentiations, N= 4 donors for PHHs. Significance was
compared with PHHs by unpaired two-tailed Student’s t-test. d Functional comparison between HLC D20 and PHH 12 h for albumin secretion and BFC
metabolisation. N= 3 independent differentiations, N= 3 donors for suspension PHH 0 h and plated PHH 12 h. Significance was compared with PHH 0 h
(BFC metabolisation) or with PHH 12 h (Albumin secretion) by unpaired two-tailed Student’s t-test. e t-SNE plot representing HLCs generated by different
protocols and PHHs. f WGCNA analysis for genes differentially expressed between HLCs to PHHs. g Representation of correlation of molecular pathways
to different modules. Correlation was shown as strong (red color) or weak (green color). h Glucose uptake/secretion over 24 h of culture in differentiating
HLCs and cultured PHHs, N= 3 independent differentiations, N= 3 donors for PHHs. Significance was compared with PHH 12 h by unpaired two-tailed
Student’s t-test. i Oxygen consumption rates with addition of oligomycin, FCCP, and antimycin for HLCs (D0 and D20), PHH 12 h, and PHH-72h. N= 6
wells, 5 time point measurements per well. For PHHs, N= 6 wells for each of 2 donors, 5 time point measurements per well. Data in all panels represent
mean ± SEM with P-values indicated when significant. Source data are provided as a Source Data file.
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As HC3X D20 could be cultured in the absence of glucose, we
next evaluated which nutrients fueled the central carbon
metabolism of PSCs, HLC D20, and HC3X D20 in vitro. We
cultured the different cell populations with 13C-labeled tracers for
glucose, glutamine, and pyruvate, and measured their contribu-
tion to glycolytic (pyruvate, lactate, and alanine) and tricarboxylic
acid cycle (TCA) (alpha-ketoglutarate, succinate, and fumarate)
metabolites. Undifferentiated HLC (D0) and HLC D20 showed
high glucose-derived 13C labeling of glycolytic metabolites and
high glutamine-derived 13C labeling of TCA metabolites (Fig. 2e).
Consistent with the consumption data, the contribution of 13C
pyruvate was significantly increased in all intermediates in HC3X
D20, which was even more pronounced upon glucose withdrawal
(Fig. 2f). Hence, although overexpression of hepatic TFs could
induce a metabolic switch from a glucose to a pyruvate-fueled
metabolism, they could not induce a gluconeogenic and oxidative
phenotype, and CYP450 function was only modestly increased.
Amino acid levels are limiting in hepatic culture media. To
compare the glucose and pyruvate dependency of HLC D20 and
HC3X D20 with the nutrient requirements of PHHs, we next
performed the same tracer studies on PHHs. Interestingly, PHHs
were found to be fueled mainly by unlabeled carbon sources
(Fig. 3a). This led us to the hypothesis that AAs, the only other
available carbon source, may represent a major carbon fuel for
hepatocytes. Consistent with this, medium recovered following
24 h of PHH culture in William’s E (WE)-based hepatocyte
maintenance medium was significantly depleted of pyruvate and
several AAs. Surprisingly, this was even more pronounced for
HLC D20 and HC3X D20 cultured in the AA-poor liver differ-
entiation medium (LDM) (Fig. 3b). Therefore, we hypothesized
that lack of AAs was responsible for the observed glucose or
pyruvate dependency. To demonstrate that HLC D20 and HC3X
D20 preferentially catabolize AAs, we performed labeling studies
with 13C leucine (5 mM). In both cell models, we detected
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Fig. 2 Overexpression of HNF1A, FOXA3, and PROX1 induces partial functional and metabolic maturation. a Relative gene expression analysis. N= 3
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with addition of oligomycin, FCCP, and antimycin for HC3X D20 cultured with glucose (HC3X D20) or without glucose (HC3X D20 –GLUC). Data for HLC
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images of two independent differentiations for PEPCK staining of HLC D20 and HC3X D20 cultured in LDM or AA3. f Glucose uptake or secretion in HLC
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Data file.
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extensive13C labeling of TCA metabolites and, to a lesser extent,
of glycolytic metabolites (Fig. 3c). Based on these results, we
cultured HLCs and HC3X progeny in the AA-rich WE-based
hepatocyte maintenance medium used commonly to culture
PHHs or we supplemented LDM medium with increasing con-
centrations of AAs (Supplementary Table 1). Surprisingly, only
the supplementation of AAs to levels well beyond those present in
WE medium increased transcripts for gluconeogenesis genes in
both HLC D20 and HC3X D20 (Fig. 3d). Only in AA3 medium,
containing five times higher concentrations of AAs than in WE
medium, ±100% of cells stained positive for PEPCK (Fig. 3e).
When differentiated in AA3 medium, HC3X D20 produced and
secreted glucose (Fig. 3f), even if this was not seen for HLC D20.
Furthermore, 13C-tracing studies suggested a switch towards AA
catabolism as observed in PHHs (Supplementary Fig. 3A). In
addition, only when HLC D20 and HC3X D20 were cultured in
AA3 medium, we observed AA uptake and urea secretion rates
that were equal to PHH 12 h (Supplementary Fig. 3C, D).
As AAs induced transcriptional upregulation of gluconeogenic
genes, we hypothesized that they not only served as carbon sources
but might act as active drivers of the hepatic phenotype. However,
when we measured the composition of the interstitial fluid (IF) of
the mouse liver, we found the concentration of most AAs to be
higher than in serum or LDM, but lower than in AA3 medium,
whereas three AAs (glutamine, alanine, and glycine) were present
at levels similar to those in AA3 medium (Supplementary Fig. 3B,
C). As only the AA3 formulation could double the basal OCR
(Fig. 3g), we believe this data suggests that in a static in-vitro
differentiation system, AA levels need to be increased above in-vivo
physiological levels to induce full metabolic maturation.
Elevating AA levels induces hepatic maturation. Surprisingly,
despite the clear correlation between metabolism, AA catabolism,
and CYP450 expression observed in the WGCNA (Fig. 1f, g),
AA3 only marginally induced the expression of CYP3A4 (Fig. 4a).
However, AAs were found to drive metabolic maturation in a
concentration-dependent manner (Fig. 3d) when exceeding the
nutritional need (Supplementary Fig. 3B, C). As glycine and
alanine concentrations greatly exceeded those of other AAs in the
mouse liver IF, we hypothesized that additional supplementation
of, e.g., glycine or alanine might induce further maturation.
We observed a concentration-dependent increase in CYP3A4
expression when HLC D20 or HC3X D20 were differentiated in
AA3 medium supplemented with 2% glycine (AAGLY) (Fig. 4a).
Furthermore, we achieved a similar induction through the addi-
tion of 2% serine, alanine, or leucine, whereas CYP3A4 was sig-
nificantly less induced following supplementation with proline,
isoleucine, and valine, or a mixture of AAs that together con-
stituted 2% (Fig. 4b). Of note, maturation was only achieved
when the 2% dimethylsulfoxide (DMSO) present in the media
was replaced by 2% of a single AA, as the combination increased
the osmolarity of the media to lethal levels (Supplementary
Fig. 4A). As aside from CYP3A4, also other CYP450 isoforms
were induced in AAGLY medium (Supplementary Fig. 4B), AAs
represent a valuable tool to induce CYP450 enzymes. Impor-
tantly, AAGLY medium induced a gradual maturation of HLC
and HC3X progeny, as extended culture resulted in a continuous
increase in CYP3A4 expression (Fig. 4c) and function (Fig. 4d) to
levels that were in the range of gold standard, freshly thawed
PHHs.
To determine whether AAGLY medium induced global
maturation, we next compared the transcriptome of HLCs and
HC3X cells differentiated in the different media with that of
PHHs. The top deregulated pathways when comparing HLC LDM
D20 with PHHs contained several genes involved in AA
catabolism, glucose metabolism, metabolic pathways, and meta-
bolism of xenobiotics by CYP450 enzymes (Fig. 4e). The same
analysis, comparing HLC LDM D20 cells with HLC AAGLY D40
cells, showed AAGLY culture medium to induce several metabolic
signaling pathways (including mammalian target of rapamycin
(mTORC1) and AMP-activated protein kinase (AMPK)) (Fig. 4f).
In general, we found both HLC D40 and HC3X D40 cells cultured
in AAGLY media to cluster and move increasingly closer to PHHs
(Fig. 4g). As AAGLY conditions regulated the expression of a large
number of genes (Supplementary Fig. 4C), we next stratified these
into four quadrants. Q1 and Q3 represented genes with similar
expression in HLC AAGLY D40 cells and PHH, but not in HLC
LDM D20 cells (normalized); Q2 represented genes that were
induced to levels higher than that found in PHHs (overexpressed);
and Q4 represented genes that remained less expressed in HLC
AAGLY D40. As shown in Fig. 5h, normalized pathways were
linked to metabolic regulation and mitochondrial function.
Overexpressed pathways contained metabolic signaling pathways,
whereas AA catabolism pathways were still expressed lower than
in PHH. These results show the addition of AAs in the culture
media is necessary to normalize the hepatic profile through
metabolic signaling pathways.
Amino acids regulate the hepatic transcriptome. To further
substantiate the hypothesis that AA levels and metabolism are a
direct determinant of hepatic functionality, we tested whether we
could use AAs to drive maturation of other hepatic models. We
found AAGLY to induce several CYP450 isoforms in the HepG2
and HUH7.5 hepatic cell lines (Supplementary Fig. 5A), whereas
again glycine could be replaced by serine, alanine, or leucine
(Supplementary Fig. 5B). Of note, we also found an AAGLY-
mediated induction of CYP1A2 and CYP2E1 in the embryonic
kidney line, HEK293 (Supplementary Fig. 5A). As both isoforms
are expressed in kidney cells32, this may suggest that AAs might
also regulate CYP450 isoforms in other cell types. Although
AAGLY medium slowed down the proliferation of several hepatic
cell lines, only HepG2 could be maintained long-term in AAGLY
medium as a uniform monolayer (Supplementary Fig. 5C). As we
observed for HLCs, AAGLY also induced a gradual increase in
CYP3A4 expression (Fig. 5a) and function (Fig. 5b) of HepG2
cells over time.
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis
of the differentially expressed genes (DEGs) in the transcriptome
of HepG2 vs. PHHs revealed that the immature phenotype
observed in HepG2 was also linked to metabolic pathways,
mitogen-activated protein kinase (MAPK) and peroxisome
proliferator-activated receptor (PPAR) signaling, and AA cata-
bolism (Fig. 5c). As in the HLC model, AAGLY supplementation
resulted in a global improvement of the HepG2 transcriptome
(Fig. 5d), specifically by modifying the expression of metabolic
and proliferative pathways (Fig. 5e). The quadrant analysis
showed metabolic and WNT signaling, combined with pathways
involved in cell cycle control and glycolysis to be normalized
following culture of HepG2 in AAGLY (Q1 and Q3). Over-
expressed pathways contained mitochondrial signaling and
OXPHOS genes (Q2), whereas pathways that were still less
expressed in HepG2 AAGLY D30 vs. PHH D0 mainly consisted
of AA catabolism genes (Q4). Thus, culture of HepG2 in AAGLY
medium phenocopied the majority of metabolic maturation
features also observed in HLC and HC3X (Fig. 5f).
Amino acids drive differentiation through metabolic signaling.
Based on the RNAseq data, we next analyzed the activity of the
AKT-mTORC1, AMPK, and eIF2alpha pathways in HepG2 cul-
tured with AA3 ALA or AA3GLY (strong inducers of CYP3A4) vs.
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Fig. 4 Elevating AA levels induces time-dependent maturation of HLC and HC3X progeny. a–c Relative CYP3A4 expression in (a) HLC D20 and HC3X
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and in AAGLY medium at D20, D40, and D50 of differentiation; (c) in HLCs cultured in medium supplemented with AA3 with or without 2% of either
glycine (GLY), serine (SER), alanine (ALA), leucine (LEU), proline (PRO), isoleucine (iLEU), aspartate (ASP), valine (VAL), or a mix of all of the above. N=
3 independent differentiations. Significance was calculated compared with HLC or HC3X LDM D20 with 2% DMSO by unpaired two-tailed Student’s t-test.
d Relative CYP3A4/CYP2E1-dependent BFC metabolization for HLCs and HC3X grown in different media conditions at different times of differentiation and
compared with PHHs. N= 3 independent differentiations. N= 4 donors for PHH 0 h and PHH 12 h. Significance was compared with PHH 0 h by unpaired
two-tailed Student’s t-test. e, f IPA analysis showing major differentially expressed pathways when comparing HLC LDM D20 with (e) PHH 0 h and
(f) HLC AAGLY D40. g PCA plot showing the distribution of HLCs and HC3X differentiated in different media and compared with PHH 0 h. h Quadrant
analysis showing pathways that are normalized (Q1 and Q3), overexpressed (Q2), or underexpressed (Q4) when comparing HLC LDM D20 with PHH 0 h
and HLC AAGLY D40. Color intensity correlates with −log(p). Data in all panels represent mean ± SEM with P-values indicated when significant. Source
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AA3 VAL (weak induction of CYP3A4). This analysis linked
induction of mature hepatic markers such as CYP3A4, PEPCK, and
glutamine synthetase to an increased phosphorylation of S6, AMPK,
and AKT. Although we did not find differences in eIF2alpha
phosphorylation, we observed a decrease of the eIF2alpha target
gene and AA deprivation factor ATF4 (ref. 33) (Supplementary
Fig. 6A). From these pathways, we were able to specifically link
mTORC1 signaling to the induction of CYP3A4, as addition of the
mTORC1 inhibitor rapamycin blocked the induction of CYP3A4,
while AMPK phosphorylation and ATF4 levels remained unchan-
ged (Supplementary Fig. 6A). Furthermore, knockout (KO) of the
upstream regulators of AMPK and eIF2alpha, LKB1 and GCN2, did
not affect CYP3A4 levels both in control media or AAGLY media
(Supplementary Fig. 6B, C). In both HepG2 (Fig. 6a), HLC and
HC3X (Fig. 6b), mTORC1 appeared to regulate CYP3A4 expression
rather than translation. Finally, although KO of the mTORC1
inhibitor Tuberous sclerosis (TSC)1 was not sufficient for driving
maturation in HepG2, culture of TSC1 KO HepG2 in AAGLY
medium yielded an even greater induction of CYP3A4 compared
with wild-type HepG2 (Fig. 6a, c). This data suggests a crucial, but
not sufficient role, for the activation of mTORC1 in inducing
CYP3A4.
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Fig. 5 High amino acid concentrations allow for further maturation over time of CYP450 enzymes in HepG2. a Gene expression analysis for CYP3A4 in
HepG2 grown for an extended time in AAGLY-supplemented medium and compared with freshly thawed PHHs. N= 3 independent maturations of HepG2
cells. N= 4 donors for PHHs. Data on PHHs was repeated from Fig. 4. Significance was calculated by comparing with PHH 0 h by unpaired two-tailed
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comparing with PHH 0 h by unpaired two-tailed Student’s t-test. c IPA comparing HepG2 with PHHs. d IPA comparing HepG2 with HepG2 AAGLY D30.
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comparing HepG2 with PHH 0 h and HepG2 AAGLY D30. Color intensity correlates with −log(p). Data in all panels represent mean ± SEM with P-values
indicated when significant. Source data are provided as a Source Data file.
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To identify downstream targets of mTORC1, we performed a
landscape in-silico subtraction analysis (LISA)34. This demon-
strated that AAGLY-mediated maturation is likely driven by
hepatic TFs and genes involved in PGC-1α-dependent mitochon-
drial biogenesis (Fig. 6d). PGC-1α-mediated mitochondrial
biogenesis was recently described as an essential regulator of
hepatic maturation28, represents a cofactor for PPARs35, and is
regulated by mTORC1 (ref. 36), sirtuins (SIRT)37 and AMPK38.
As our transcriptome analysis showed normalization of mito-
chondrial function (Figs. 4g and 5g), we subsequently tested if
AAGLY-induced differentiation was correlated with mitochon-
drial biogenesis. We found that supplementation with AAGLY
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combination with rapamycin addition (RAPA), or using HepG2 wherein TSC1, GCN2, or LKB1 were knocked out. N= 3 independent differentiations.
Significance was calculated by comparing against HepG2 CTL. Significance was also calculated between Hepg2 AAGLY D30 and HepG2 AAGLY RAPA,
and between HepG2 AAGLY D30 and TSC1 KO AAGLY D30 when indicated. Significance was calculated by unpaired two-tailed Student’s t-test. b Relative
gene expression analysis for CYP3A4 in HLC and HC3X differentiated with AAGLY until D20, with or without rapamycin (RAPA). Expression of HLCs and
HC3X cells was related to differentiations in LDM. N= 3 independent differentiations. Significance was calculated by comparing against the LDM and
between LDM AA3GLY and LDM AA3GLY RAPA by two-tailed unpaired Student’s t-test. cWestern blotting analysis comparing the phosphorylation of S6
and the expression of ATF4 and CYP3A4 in HepG2 differentiated in control media or AAGLY media, with or without KO of TSC1. Representative blot of two
repeats. d LISA analysis identifying the top TFs responsible for the genome wide difference between HepG2 and HLC grown in control or AAGLY media.
e BFC metabolization comparing HC6X LDM D40 and HC6X AAGLY D40/50, as well as HC6X AAGLY D40 where doxycycline was removed from d30
onwards (HC6X AAGLY D40-DOX from D30). N= 3 independent differentiations. N= 3 donors for PHHs. Significance was calculated as compared with
PHH 0 h by unpaired two-tailed Student’s t-test. Significance was also calculated between HC6X AAGLY D40 and HC6X AAGLY –DOX D30-D40. f PCA
plot showing the distribution of HLCs, HC3X, and HC6X differentiated in different media and compared with PHHs. Data in all panels represent mean ±
SEM with P-values indicated when significant. Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15058-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1393 | https://doi.org/10.1038/s41467-020-15058-6 | www.nature.com/naturecommunications 9
induced a significant increase in HepG2 cell size and mitochon-
drial mass (measured by the corrected total cell fluorescence
(CTCF) for the mitochondrial import receptor subunit TOMM20
homolog (TOMM20)) (Supplementary Fig. 6C). Moreover, the
activity of the electron transport chain (ETC) and the
mitochondrial enzyme, citrate synthase, were all induced by
AAGLY supplementation (Supplementary Fig. 6D). To determine
whether the effect on mitochondrial biogenesis and hepatic
maturation induced by AAGLY could be replaced by incorpora-
tion of TFs induced by AAGLY supplementation, we integrated
an inducible PGC-1α (PGC1A cells) cassette alone or a cassette
containing the three inducible TFs already present in the HC3X
line, together with an inducible cassette containing the PGC-1α
complementary DNA, as well as the cDNA for its posttranscrip-
tional regulator SIRT1 and a constitutively active variant of
AMPK (HC6X). Addition of doxycycline induced transcript levels
of PGC-1α (PGC1A cells) alone or all six TFs (HC6X) near levels
seen in PHHs. However, expression of the ETC components such
as cyclooxygenase (COX)1, cytochrome (CYT)C, and ATP
synthase (ATP)5A1 were only induced in HC6X progeny and
not PGC-1α progeny (Supplementary Fig. 6F). In HC6X D40,
cultured in LDM, we observed an induction in mitochondrial
mass similar to that of HLCs or HC3X cultured in AAGLY
medium (Supplementary Fig. 6G). However, we only found an
increase in CYP3A4 and the gluconeogenic genes, G6PC and
PEPCK, when HC6X were also cultured with AAGLY, indicating
that mitochondrial biogenesis is not sufficient to drive maturation
(Supplementary Fig. 6E, F). The transcriptome of HC6X AAGLY
D40 was similar to that of HC3X AAGLY D40, even if perhaps
slightly closer to that of PHHs (Fig. 6f). Of note, removal of
doxycycline from D30 onwards (HC6X AAGLY D40-DOX from
D30) caused a significant decrease in CYP3A4 activity (Fig. 6e)
and to a lesser extent also decreased global maturity (Fig. 6f).
These results indicate that although overexpression of hepatic TFs
only has a minimal effect in the context of standard culture
media, AAGLY conditions allow hepatic TFs to drive maturation.
Indeed, a LISA analysis comparing HC6X AAGLY D40 with
HC6X AAGLY D40-DOX from D30 showed that the major
difference between both cell populations is due to the activity of
hepatic TFs (Supplementary Fig. 6G).
AAGLY-mediated maturation enables identification of hepa-
totoxicants. Given the acquisition of a more mature phenotype in
both HepG2 cells and PSC- hepatic progeny, we next evaluated
the ability of these cells to biotransform drugs and predict drug-
induced liver injury (DILI) in comparison with standard models
including PHHs39, HepaRG cells9, and the micropatterned PHH-
based Hepatopac® system5. First, we evaluated biotransformation
of midazolam, dextromethorphan, tolbutamide, and phenacetin
by HepG2 AAGLY D32 and HC6X AAGLY D40 after a single
exposure. As shown in Fig. 7a, the biotransformation rates for all
drugs were found to be in the range of the PHH-based Hepato-
pac® system and surpassed that of the HepaRG model. More
specifically, midazolam biotransformation was equal to that of
PHHs, whereas the biotransformation by CYP2D6, CYP1A2, and
CYP2C9 were found to be in the range of 1–10% of the best PHH
donor22,40,41. Importantly, drug biotransformation remained
stable for at least 10 days (Supplementary Fig. 7A). In accordance,
we found that HC6X AAGLY D40 stained positive for CYP3A4,
with several cells displaying a binucleated phenotype (Supple-
mentary Fig. 7B).
To evaluate the ability to predict hepatotoxicity, we adapted
the differentiation assays to a 384-well format. First, we tested
sensitivity to a single administration of amiodarone and
acetaminophen (APAP) (both requiring CYP450-dependent
metabolization), and to the mitochondrial toxin rotenone, known
to be highly toxic for PHHs. Although no toxicity was seen for
HepG2, HLC, and HC6X cultured in basal medium, exposure of
all three cell types cultured in AAGLY-supplemented medium to
these drugs resulted in sigmoidal kill curves and EC50 values that
were similar to PHHs, and in line with previously published
PHH-based toxicity studies5,42. Most importantly, all models
were stable, as similar drug toxicity was seen after an additional
10 days of culture. Moreover, generation and differentiation of an
HC6X cell line in an iPSC background (BJ1) yielded very similar
results (Fig. 7b, Supplementary Fig. 7C, and Supplementary
Table 2). We also addressed the ability of HepG2, HLC, HC3X,
and HC6X, cultured in basal medium or medium supplemented
with AAGLY, to predict DILI. We used the protocol described by
Sison-Young et al.43, based on repeated administration of 13 gold
standard DILI training compounds. As a readout, we evaluated
cell viability by resazurin conversion and correlated the results to
therapeutic doses (Cmax values). As shown in Fig. 7c and
Supplementary Fig. 7C, we found HC6X AAGLY D40 or HC3X
AAGLY D40 to perform the best when using an EC50/Cmax cut-
off= 10 or 20, respectively. Although AAGLY also increased
sensitivity in the HepG2 model, here several drugs were still
identified as false negative. Last, removal of doxycycline in the last
10 days of differentiation had a detrimental effect on drug
sensitivity (HC6X AAGLY D40 vs. HC6X AAGLY D40-DOX
from D30). This reinforces the notion that a combinatorial
approach of metabolic and genome engineering creates the most
optimal PSC progeny (Fig. 7c and Supplementary Fig. 7C). In
conclusion, AAGLY-mediated maturation greatly increases drug
sensitivity in both HepG2 and PSC-based models, but only the
HC3X AAGLY D40 and HC6X AAGLY D40 cells were found to
identify hepatotoxicants to a similar extent as PHHs43.
Discussion
In this study, we identified AAs as important regulators of hepatic
metabolism and function in an in-vitro setting. Specifically, we
demonstrate that elevating AA levels beyond the nutritional need
can transcriptionally drive the transformation from a glucose-
dependent to an AA-fueled and glucose-producing metabolic
profile. Furthermore, we show that AAs feed into the regulation
of the hepatic transcriptional network and thus drive, in a
manner that is similar to growth factors, hepatic differentiation.
As a consequence, AAs can be used as a tool to induce maturation
of HLCs and hepatic cell lines. Indeed, cells grown in AAGLY
conditions acquire the capability to biotransform drugs at levels
similar to PHHs40,41 and are able to stratify DILI training com-
pounds at similar levels as PHHs43. Therefore, we propose
nutrient engineering as a complementary strategy to growth
factor treatment, ECM engineering, transcription factor over-
expression, and organoid cultures in the context of PSC hepato-
cyte differentiation and maturation26.
The observation that nutrients can actively influence cellular
maturation is in line with recent publications demonstrating that
the removal of glutamine can boost the pluripotency network44,
that addition of oxidized metabolites can drive differentiation
towards the neuronal lineage27, and that lactate allows purifying
cardiomyocytes45. In the context of hepatocyte differentiation, no
such studies have been performed. Hepatocytes are among the
metabolically most active cells, containing a highly elaborate
mitochondrial network28, and mitochondrial dysfunction has
been implicated in several liver-related diseases46,47. In addition, a
few studies have suggested that the overall metabolite concentra-
tions are much higher in adult than fetal cultured hepatocytes48,
and that cultured PHHs are in an extremely starved state49. Our
data suggest that HLCs and HepG2 grown in standard conditions
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indeed experience suboptimal AA levels. However, we also show
that full functional maturation and the induction of drug bio-
transformation requires the addition of AAs beyond the nutri-
tional need of HLCs or HepG2. Thus, although previous studies
identified AAs as important for hepatocyte survival, proliferation,
and protein synthesis50,51, we here demonstrate that increasing
AAs to levels 30-fold above that of typical hepatocyte media,
actively induces a metabolic switch, as well as CYP450 enzyme
expression and function (Supplementary Table 3). Of note, AA
levels in the liver IF have been described to exceed that of serum52,
which we confirmed here, and are believed to fuel glucose, urea,
and protein production in a concentration-dependent manner
in vivo53. Although we demonstrate AA requirements for indu-
cing in-vitro differentiation to be supra-physiological, it is difficult
to compare a perfused (in vivo) to a static (in vitro) state. This
would be in line with the fact that in many instances supra-
physiological concentrations of growth factors are used in vitro54,
further reinforcing the notion of AAs as signaling molecules. This
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study therefore demonstrates that AAs represent a tool to
manipulate stem cell differentiation, as has already been shown in
the cancer metabolism field55–57.
Of the investigated signaling pathways, we only found inhibi-
tion of mTORC1 to be able to prevent the induction of CYP3A4
under conditions of AA supplementation. Activation of mTORC1
has been shown to be important for liver regeneration and
hepatocyte maturation in vivo58,59. Nevertheless, the sole acti-
vation of mTORC1 through the genetic deletion of TSC1 was not
sufficient to induce CYP3A4 expression. This finding could be in
line with studies demonstrating that TSC2 KO in mouse
embryonic feeders (MEFs) does not cause mTOR/S6K activation
when cultured under AA-deprived conditions60, and that
mTORC1 signaling requires metabolic fluxes such as autophagic
lipid catabolism to sustain mTORC1 signaling, even following
genetic ativation61. Alternatively, AAGLY likely induces several
other metabolic signaling pathways other than mTORC1. In fact,
our RNAseq studies demonstrate that AAs have a global effect on
hepatic maturation and target multiple aspects of hepatic biology,
including WNT, BMP, and cAMP signaling. This result is in
accordance with a recent paper identifying a culture system for
the long-term maintenance of PHH functionality through the
simultaneous pharmacological manipulation of 5 key signaling
pathways (TGF-β, Notch, WNT, BMP, and cAMP)7. Thus, it
appears that at least three of these pathways are not only involved
in maintaining a mature hepatocyte phenotype, but also drive
maturation of immature cell populations. Moreover, our data
suggest that this can be achieved via a nutritional rather than
pharmacological approach. To link the activation of these path-
ways to hepatic maturation, we mapped the TFs that are
responsible for the difference between cells differentiated in
standard media and in AAGLY. In this analysis, we found liver
TFs, such as the CYP450-linked Kruppel-like factor 15 (ref. 62)
and HNF4α63, to be the major regulators. Therefore, we believe
that AAGLY conditions are a requirement for the hepatic tran-
scriptional network to drive maturation, whereas the over-
expression of TFs has a complementary effect. Last, AAGLY
supplementation allows for a gradual maturation of both PSC
progeny and HepG2 over 30–40 days. This suggests that the
AAGLY supplementation induces several transcriptional and
perhaps epigenetic mechanisms that ultimately lead to a pheno-
typic maturation. Therefore, the low levels of AA in standard
media for HLCs and HepG2 cells may represent a block in
hepatic maturation.
Finally, we demonstrate that the AAGLY-supplemented mod-
els display drug biotransformation that approaches that of the
current gold standard PHHs39,64. We also observed that espe-
cially the combined genome and nutrient engineering strategy
allowed for the best prediction of DILI. HC3X- and HC6X
AAGLY D40 cell correctly identify seven out of nine hepatotoxins
(at EC50/Cmax= 20). These results are similar to the average of
the seven PHH populations described by Sison-Young et al.43. In
contrast to PHHs cultured in classical 2D culture conditions, we
also show that both HepG2 and HC6X differentiated in AAGLY
medium maintain stable drug biotransformation and drug sen-
sitivity for at least 10 days, indicating their suitability for repeat
dose toxicity and long-term drug biotransformation studies. In
conclusion, this study highlights nutrients as a potential tool to
guide hepatic maturation in several cell models. The optimization
described creates significantly improved and long-term stable
models for studying hepatocyte biology, drug biotransformation,
and identification of liver toxicants.
Methods
hPSC differentiation to the hepatocyte lineage. The human embryonic stem
cell (hESC) line H9 (WA09) was purchased from WiCell Research Institute
(Madison, 15 WI) and kept according to supplier’s instructions as feeder-free
cultures on Matrigel (BD biosciences)-coated plates in Essential 8 (or Essential 8
Flex) (Thermo fisher). BJ1 iPSCs were made in-house and kept on Matrigel-coated
plates at ±8.75 × 104 cells/cm2 in mTeSR medium (Stem Cell Technologies)65. Cells
were differentiated towards the hepatocyte lineage as described by our group
before65, with some optimizations. Briefly, single-cell suspensions of H9/ BJ1 cells
(using accutase) were plated on Matrigel-coated plates at ±8.75 × 104 cells/cm2 in
mTeSR medium (Stem Cell Technologies). When cells reached 70–80% confluency,
differentiation was started using the previously described cytokine regimes and was
stopped after 20 days of differentiation. All cytokines were purchased from
Peprotech (NJ). Differentiation medium was supplemented with 0.6% DMSO
during the first 12 days of the culture and with 2% DMSO during the last 8 days of
differentiation. Use of embryonic stem cells and iPSCs for research was approved
by the “Commissie Medische Ethiek,” UZ KU Leuven/Onderzoek U.Z. Gasthuis-
berg, Herestraat 49, B 3000 Leuven, under file number S52426
Primary cells. As positive control for hepatic expression and function, two donors
(C304 (male, 64 years of age) and C303 (female, 52 years of age)) of crypopreserved
and platable PHHs were bought from Corning Biosciences (Corning® Gentest™
Plateable Human CryoHepatocytes, Metabolism-Qualified, ≥5 million cells (Pro-
duct #454543)). Furthermore, two additional donors (donor F125 (male, 62 years
of age) and donor F110 (female, 26 years of age)) were obtained from the Ministery
of Health-accredited tissue banks at the Cliniques Univeristaires St Luc, Brussels.
This post-mortem collected tissue was obtained under the Belgian legislation on
organ and tissue donation. The organ collected within the opting out system
supposes that the deceased donor of his representative has made no opposition for
organ donation, including for research purpose. All four donors were used for gene
expression assessment, whereas Seahorse and toxicity experiments were performed
on donor C303 and F125. Functional characterization was performed on donors
C3030, F125, and C303. Primary cells were thawed using the Corning® Gentest™
High Viability CryoHepatocyte Recovery Kit (Corning) and plated on collagen I-
coated plates.
Recombinase-mediated cassette exchange. The master cell lines suitable for
RMCE were generated using zinc-finger mediated integration of a flippase
recombinase target-flanked donor cassette into the AAVS1 locus and are avail-
able31. RMCE was performed by nucleofection of the master cell line with a donor
vector and the FLPe-expressing vector. Nucleofection was done on 3 million cells
obtained after accutase treatment using the hESC Nucleofector Solution Kit 2
(Amaxa) and program F16 using an Amaxa nucleoporator. Cells were plated on
puromycin-resistant MEFs (Stem Cell Technologies, Puromycin-Resistant Mouse
Embryonic Fibroblasts, Day E13.5) in hESC medium66. Donor plasmids were
generated through Gibson assembly (NEB) of PCR-amplified open reading frames
of the desired genes. Plasmids were then evaluated by digestion and Sanger
sequencing. The constitutively active AMPK construct was bought from Addgene
(plasmid number 60127) and was generated by the lab of Professor Morris
Fig. 7 AA supplementation allows for hepatotoxic drug screening in a high-throughput format. a CYP3A4-dependent formation of 1-OH midazolam and
CYP450-dependent biotransformation of dextromethorphan (2D6), phenacetin (1A2), and tolbutamide (2C9) after 1 h of treatment. Treated cells consist
of PHHs maintained in suspension from two donors (PHH1 and PHH2) (N= 3 thawings), the Hepatopac® system (N= 3 donors), HC6X differentiated in
either LDM or AAGLY for 40 days (N= 3 independent differentiations), and HepG2 in control media (HepG2 CTL D4) or differentiated in AAGLY for
30 days (HepG2 AAGLY D30) (N= 3 independent maturations), and HepaRG cells (N= 8 differentiations). Undetectable values are not shown on the
logarithmic scale. b EC50 values for amiodarone, APAP, and rotenone for cells cultured in control or AAGLY medium. Cultures consist of PHHs cultured for
12 h (PHH 12 h), HepG2 cultured for 7 days in control media (Hepg2 CTL D7), or differentiated for 30 days in AAGLY (HepG2 AAGLY D30), HLCs, and
HC6X in the H9-ESC or BJ1-iPSC background differentiated for 40 days in either LDM or in AAGLY; N= 6 separate well per concentration for treated cells.
N= 18 separate wells for control cells. One donor of PHHs was analyzed in six wells. Viability was determined by Hoechst and Draq7 staining. c EC50/Cmax
values for nine hepatotoxic and four non-hepatotoxic training compounds. Cell viability was measured by resazurin conversion. Data in all panels represent
mean ± SEM. Source data are provided as a Source Data file.
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(University of Pennsylvania). The flow cytometry gating strategy for evaluating loss
of green fluorescent protein signal is illustrated in Supplementary Fig. 8
Media optimization and composition. Differentiation of PSCs (and genetically
modified PSCs) was performed in LDM as previously described65 (the composition
is listed in Supplementary Table 4). 13C-labeled carbon sources were added to
medium, made from powder of Dulbecco’s modified Eagle’s medium (DMEM)
without glucose, L-glutamine, phenol red, sodium pyruvate, and sodium bicarbo-
nate. As Molecular, Cellular, and Development Biology (MCDB) media also
contains glucose, the MCDB component of LDM was replaced by DMEM.
AA supplementation was accomplished through the addition of MEM Non-
Essential Amino Acids Solution (100 × ) and MEM Amino Acids Solution (50 × )
(Thermo Scientific) to the culture medium. For AA1, AA2, and AA3 medium, we
added respectively 2 ml, 8 ml, and 16 ml of non-essential AA solution and 1 ml,
4 ml, and 8 ml of essential AA solution per 100 ml of LDM, with or without
glucose. Culture medium was then made PH neutral through the addition of
NaOH. Addition of glycine or any other of the single AAs was accomplished by
adding 20 g/l of each AA powder (Sigma). PSC derived HLCs were differentiated in
LDM until D12. AA supplementation (AA1, AA2 and AA3) was performed from
day 12 until day 20, 30 or 40 of differentiation. Removal of glucose and/or addition
of glycine (or other single AAs) at 20 g/l was done from D14 onwards. Upon
addition of glycine, DMSO was removed from the culture media. HepG2, HUH7.5,
Hep3B, HHL5, and HEK293 cells were maintained in DMEM supplemented with
10% fetal bovine serum as shown in Supplementary Table 4. AA supplementation
consisted of addition of 16 ml of non-essential AA mix and 8 ml of essential AA
mix per 100 ml of medium and a further addition of 20 g/l of any of the single AAs.
Hepatoma cell lines were plated in normal culture medium, with addition of
AA3+ 20 g/l AA once cells reached 60% confluency, and this for 3 or 7 additional
days of culture. PHHs were maintained in a medium composition that was based
on WE as detailed in ref. 67.
Intracellular AAT flow cytometry. Single-cell suspensions of d20 PSC progeny
(following trypsinization with 0.25% Trypsin) were fixed with 4% paraformalde-
hyde (PFA) for 15 min, permeabilized with 0.1% saponin for 15 min, and blocked
with 10% goat serum (Dako, 15 Glostrup, Denmark) for 45 min, all at room
temperature. Samples were stained using 0.0625 µg/200 µl of the anti-AAT anti-
body (Dako) for 1 h followed by an Alexa Fluor 647 secondary antibody (1:1500)
(Invitrogen) for 30 min and analyzed using a FACS-Canto (BD Biosciences). As
isotype control, we used rabbit IgG (BD Pharmingen). The gating strategy is
illustrated in Supplementary Fig. 9.
Immunofluorescence staining. Cells were fixed with 4% PFA for 15 min at room
temperature. After permeabilization with 0.2% Triton X-100 for 15 min, samples
were blocked with 10% donkey goat serum (Dako, 15 Glostrup, Denmark) for
15 min. Staining with the primary antibodies and isotype controls was performed
overnight at 4 °C. Next, the samples were stained using the corresponding sec-
ondary antibodies for 1 h and with Hoechst (Sigma-Aldrich) for 10 min. An
overview of all used antibodies and their working concentration is given in Sup-
plementary Table 5. Images were taken using an Axioimager.Z1 microscope (Carl
Zeiss). Intensity of TOMM20 staining was measured using the ImageJ Mito-
Morphology Macro68 and is shown as the CTCF, with CTCF= Integrated Density
− (Area of selected cell × Mean fluorescence of background readings).
RNA extraction and quantitative reverse-transcription PCR. RNA extraction
was performed using the GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich). Then, genomic DNA was eliminated using the On-Column DNase I
Digestion kit (Sigma-Aldrich). Last, 1 µg of RNA was transcribed to cDNA using
the Superscript III First-Strand synthesis (Invitrogen). Gene expression analysis
was performed using the Platinum SYBR green qPCR supermix-UDG kit (Invi-
trogen) in a ViiA 7 Real-Time PCR instrument (Thermo Scientific, Waltham, MA).
The sequences of all used qRT-PCR primers are listed in Supplementary Table 6.
Of these, ribosomal protein L19 (RPL19) was used as a housekeeping gene for
normalization.
RNAseq analysis. RNAseq analysis was performed by the VIB Nucleomics core
(Leuven, Belgium). RNAseq fastq files were collected, and low-quality ends and
adapter sequences were trimmed off from the Illumina reads using trimmomatic.
Processed reads were mapped and aligned with Spliced Transcripts Alignment to a
Reference (STAR) to the Human reference genome (GRCh38.91) with default
ENCODE parameter settings, except for “--runThreadN 16 --sjdbOverhang 76.”
Reads per kilobase of transcript per million mapped reads were computed using
Cufflinks and then normalized to transcripts per million (TPM). Using R Studio,
TPM was then log2 transformed before performing hierarchical clustering using
Euclidean distance and centroid linkage by unweighted centroid clustering. Prin-
cipal component analysis (PCA) was done using the “ggplot2” package in statistical
software, R. HTSeq package with Python was utilized to identify the raw counts
inputted into the “EdgeR” package in R to compute differential gene expression.
The threshold criteria of P-value and false discovery rate (FDR) ≤ 0.05, and a fold
change of ≥2 in gene expression among the different pairwise comparisons were
used to identify the DEGs. Functional analysis or Gene ontology (GO) of the
different DEGs was done utilizing DAVID v6.8, whereas pathway comparison
analysis was done in Ingenuity Pathway Analysis. Further visualizations of the data
including the PCA plot and the comparative analysis of pairwise comparisons to
perform the quadrant analysis were done using TIBCO Spotfire v7.6.1 OmicsOffice
package.
Quadrant analysis. Differential gene expression analysis was done in the statistical
software, R (v 3.3.3). Python software htseq-counts was utilized to extract the
necessary raw read counts to upload into the “EdgeR” package to determine dif-
ferential gene expression. A threshold criteria of P-value and FDR ≤ 0.05, and a fold
change of ≥2 in gene expression among the different pairwise comparisons were
then used to identify the significant DEGs. Visualizations of the pairwise com-
parisons of DEGs were elucidated in a quadrant comparative analysis done in
TIBCO Spotfire v7.6.1. Data were first filtered so that the P-value and FDR were
≤0.05 for each pairwise comparison before being represented in a scatter plot.
Weighted gene correlation network analysis. We queried ArrayExpress for
microarrays of both stem cell-derived hepatocytes and primary hepatocytes. Only
samples that were not of cancerous origin, and that were labeled with biotin, were
used for analysis. Samples were robust multichip average normalized per platform,
followed by quantile normalization to remove platform effects. Probe intensities
were summarized by the geometric mean. Only genes that were significantly dif-
ferentially expressed (Holm–Bonferroni adjusted p-value < 0.05) between HLCs
and primary hepatocytes were kept for analysis. Furthermore, we applied a cut-off
on the expression range. Transcription factors differing less than twofold over all
samples were removed, as well as other genes differing less than fourfold over all
samples. Using this cleaned dataset, we perform a signed WGCNA analysis as
described by Langfelder et al.29. A soft-thresholding power of 19 was used as to
approach scale-free topology (R2= 0.864) and highly correlated modules were
merged (cut height 0.2). To identify which pathways were dysregulated in each
cluster, we performed GO analysis using the TopGO R package and KEGG
pathway-enrichment analysis using the clusterProfiler R package.
Epigenetic landscape in-silico subtraction analysis. For the LISA analysis, we
uploaded the 500 genes with highest differential expression and a p-value of at least
0.05 into the LISA cistrome website. Top transcription factors were shown based
on −log (P) value.
Seahorse measurements. Oxygen consumption and extracellular acidification
were analyzed by differentiating the cells in Seahorse XF24 tissue culture plates
(Seahorse Bioscience Europe, Copenhagen, Denmark). The measurement of OCR
was performed at 10 min intervals (2 min mixing, 2 min recovery, and 6 min
measuring) for 3 h using the Seahorse XF24 analyzer. Cells were exposed to 1 µM of
oligomycin (Oligo) to correlate oxygen consumption with mitochondrial activity,
to 1.5 µM of FCCP, an uncoupler of the ETC, to measure maximal respiration, and
finally, to 1 µM of antimycin (Anti). Data were then normalized for protein con-
tent, quantified using the Pierce™ BCA Protein Assay Kit (Thermo Scientific,
23225) following manufacturer’s instructions.
GC and HPLC MS measurements. Metabolite extraction, derivatization, and
measurement on the gas chromatography–mass spectrometry (GC-MS) was done
as described previously69. Briefly, cellular metabolism was quenched in liquid
nitrogen. Metabolites were then obtained through a cold two-phase
methanol–water–chloroform extraction and phase separation at 4 °C, dried using a
vacuum concentrato, and stored at −80 °C. Sample derivation was accomplished by
a reaction with 7.5 µl of methoxyamine (20 mg/ml in pyridine) for 90 min at 37 °C
and with 15 µl of N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide for
60 min at 60 °C. Metabolite levels and isotopomer distribution was then measured
with a 7890 A GC system (Agilent Technologies). Isotopomer distributions were
extracted from the raw ion chromatograms using a custom Matlab M-file. Iso-
topomers were then calculated as a fraction of the total amount. Glucose, pyruvate,
and lactate concentrations were measured in the medium samples by high-
performance liquid chromatography (HPLC). Medium samples were taken at
different time points and stored at −80 °C. They were measured on a HPLC Bio
Rad organic acid analysis column, Aminex HPX-87H, Ion exclusion column,
300 mm × 7.8 mm with 5 mM H2SO4 as the mobile phase. Peeks were integrated
manually, as was a standard curve for glucose, lactate, and pyruvate made in basal
medium. For tissue samples, tissues were weighed (5–10 mg) and pulverized
(Cryomill, Retsch) under liquid nitrogen conditions. Next, −20 °C cold 65%
methanol was added to the samples, followed by −20 °C cold chloroform. Samples
were then processed as described above (GC-MS measurement). For tissue extracts,
the total ion counts were normalized to the internal standard and tissue weight.
Liver IF extraction. The liver IF extraction method has been modified and adapted
from Nagahashi et al.70 and from Wiig et al.71. Briefly, five 9-week-old, healthy
Balb/c female mice were killed with 50 µL of 60 mg/ml of Dolethal (pentobarbital
sodium). Subsequently, livers were collected by surgical resection, washed in a
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blood bank saline solution, and dried from liquid excess by tapping in a gauze.
Subsequently, the livers were placed in a filtered centrifuge tube created by using a
column-centrifuge tube in which the pre-existent filter has been substituted with a
nylon mesh filter with 20 µm opening pores (Spectrum Labs, Product code:
S145811). The IFs (around 2–5 µL for each organ) was collected in the column-
centrifuge tubes by centrifugation at 400 × g, 4 °C for 10 min, and processed
immediately after extraction. The animal study complies with ethical regulations
and was approved by the KU Leuven ethics committee. Housing and experimental
animal procedures were approved by the Institutional Animal Care and Research
Advisory Committee of KU Leuven, Belgium.
Generation of HepG2 KO cell lines. KO cell lines were generated by transducing
HepG2 cells with lentiviral particles containing the lentiCrispr v2 construct
(Addgene Plasmid #52961). After puromycin selection, gene KO was evaluated
through western blot. sgRNAs used were 5′-GCACCTTGGTGGATTATTACC-3′
for the TSC1 KO, 5′-GGAAATGCTGGACAGCGTGC-3′ for GCN2 KO, and 5′-
GGAAATGCTGGACAGCGTGC-3′ for LKB1 KO.
Functional assessments. Urea concentrations in the medium were analyzed after
24 h of culture using the QuantiChromTM Urea Assay Kit (BioAssay Systems
DIUR-500) according to the manufacturer’s instructions. CYP3A4-dependent
metabolization was determined using the fluorometric probe BFC as previously
described72. Metabolization was assessed for 1 h and 4 h incubation times. For
PHHs and data points that showed high values, samples were diluted 1/10 in buffer.
The albumin secretion rate was quantified using the human albumin ELISA
quantification kit (Bethyl) according to instructions provided in the kit.
Drug biotransformation assessment. Comparative CYP450 biotransformation
studies were performed to assess functionality across a number of gold standard
primary hepatocyte models. Cryopreserved PHHs were obtained from a single
donor (Lonza, Breda, The Netherlands) or pooled donors (Thermo Scientific,
Merelbeke, Belgium). Upon thawing, cell suspensions (0.5 million cells/ml) were
prepared in WE medium using 24-well plates (0.5 ml/well) on an orbital shaker and
metabolization activity was assessed following a 15 min equilibration period.
Human Hepatopac® plates were obtained from Ascendance Biotechnology
(Ascendance Biotechnology, Boston USA) and cultures were maintained following
instructions of the provider. Spheroid cultures were generated in-house as essen-
tially described by Bell et al.42.
To assess the respective metabolization capacities, models were treated with a
cocktail consisting of the probe substrates midazolam (10 µM), dextromethorphan
(20 µM), phenacetin (100 µM), and tolbutamide (100 µM), to determine the
activities of CYP3A4, CYP2D6, CYP1A2, and CYP2C9, respectively. Metabolite
formation was quantified on a Shimadzu Nexera SIL-30AC system (Shimadzu
Corp., Kyoto, Japan) connected to a SCIEX QTRAP 6500 mass spectrometer
(SCIEX, Ontario, Canada) (for determining 4-OH-Tolbutamide and Phenacetin)
or a SCIEX API-4000 (SCIEX) (for determining 1-OH-midazolam and
dextrorphan) equipped with an ionization source operated in negative (4-OH-
tolbutamide) or positive (1-OH-midazolam, dextrorphan, APAP) mode.
Separation was carried out at 50 °C using either a Waters Acquity C18 BEH 1.7 µm
(50 × 2.1 mm ID; Waters Corp., MA, USA) for midazolam and dextromethorphan
or a Waters Acquity HSS T3 1.8 µm (2.1 × 100 mm; Waters Corp., MA, USA) for
phenacetin or tolbutamide.
For quantification of 1-OH-midazolam and dextrorphan, a mobile phase was
established consisting of solvent A (HPLC-grade water containing 0.1% formic
acid) and solvent B (ACN). After a 2.5 min plateau at 60% (A)/40% (B), a solvent
gradient was started from 60% (A)/40% (B) to 2% (A)/98%(B) over 0.5 min at a
flow rate of 0.6 ml/min to elute the compounds from the column. Finally, the
system was re-equilibrated at 60% (A)/40% (B) for an additional 0.7 min. Total run
time was 3.8 min and 2 µl aliquots were injected onto the system for analysis.
For quantification of Phenacetin and 1-OH-tolbutamide, a mobile phase was
established consisting of solvent A (HPLC-grade water containing 0.1% (vol:vol)
acetic acid) and solvent B (methanol). After a 2 min plateau at 10% (A)/90% (B), a
solvent gradient was initiated from 10% (A)/90% (B) to 2% (A)/98%(B) over 1 min
at a flow rate of 0.4 ml/min to elute the compounds from the column, before the
system was re-equilibrated at 10% (A)/90% (B) for an additional 1.0 min. Total run
time was 5.0 min and 2 µl aliquots were injected into the system for analysis.
All data collection, processing, and analysis was performed with Analyst®
software (v1.6.2. SCIEX). The lower limit of quantification was set at 0.5 ng/ml,
2.0 ng/ml, 0.1 ng/ml, 0.1 ng/ml, and 0.5 ng/ml for APAP, 4-OH-tolbutamide,
dextrorphan, and 1-OH-midazolam, respectively.
Western blot analysis. Cells were collected and lysed in RIPA lysis (Sigma-
Aldrich) and extraction buffer (Thermo Scientific) supplemented with proteinase
(complete, Mini Protease Inhibitor Cocktail Tablets provided in a glass vial, Roche,
11836153001) and phosphatase (PhosSTOP™, Sigma, 4906845001) inhibitors.
Protein amount was measured using a pierce BCA protein assay kit (Thermo
Scientific). Aliquots of 25 µg of protein were loaded on a NuPAGE 4–12% dena-
turing Bis-Tris gel and transferred to a nitrocellulose membrane (Thermo
Scientific). Membranes were incubated overnight at 4 °C with primary antibodies
and afterwards incubated with horseradish peroxidase-linked mouse secondary
antibodies (Cell Signaling Technology #7076), and bound antibodies visualized
using Pierce ECL reagent (Thermo Scientific).
Enzymatic activity of mitochondrial proteins. The activity of citrate synthase and
the individual complexes of the ETC (complex I to complex IV) in cell lines was
determined as described before73. For HepG2 and HC3X-derived hepatocyte,
pellets from five T-150 flasks were pooled as one sample. Snap-frozen pellets were
homogenized using a glass homogenizer and motor-driven teflon plunger in
homogenization buffer containing HEPES, EGTA, and sucrose. Enriched mito-
chondrial fractions were prepared by differential centrifugation at 4 °C (600 × g for
10 min to obtain crude mitochondrial fraction in the supernatant and subsequent
144,000 × g for 10 min for the enriched fraction in the resulting pellet). All pellets,
except for those used for measuring complex III activity were resuspended in
hypotonic buffer containing potassium phosphate and MgCl2. Citrate synthase and
complex I–IV activities were determined by monitoring appearance or dis-
appearance of specific substrates at specific wavelengths using spectrophotometry
(e.g., oxidation of NADH for complex I activity at 340 nm in the presence and
absence of rotenone to evaluate complex I-specific activity, reduction of cyto-
chrome c for complex III activity at 550 nm).
Toxicity measurements upon drug administration. PSCs were differentiated in a
384-well format. Cells were treated with 14 different concentrations of compounds
in 6 repeats. As a negative control, 41 wells were left untreated. HepG2 were seeded
at 40,000 cells per well. For control conditions, HepG2 were exposed after 2 days of
culture. For AAGLY conditions, HepG2 were maintained in the supplemented
medium for 30 days before exposure. For single exposure of APAP, amiodarone,
and rotenone, medium was aspirated after 24 h of exposure and fresh medium was
added to the cells supplemented with 0.3 mM of DRAQ7 (Abcam, ab109202) and
Hoechst dye (1/1000, Sigma, 33258) for 25 min at 37 °C. Cells were fixed with 4%
PFA. Imaging was done using an Operetta High-Content Imaging System (Perkin
Elmer) and image analysis was performed using Harmony software (Perkin Elmer).
Relative cell number was calculated as the percentage of living cells (DRAQ7-
positive amount subtracted from the Hoechst-positive amount) relative to the
average of living cells in the control wells. As a positive control, 1 donor of PHHs
was seeded at 10,000 cells per well. Drugs were administrated after 8 h of attach-
ment. For repeated exposures of the 13 training compounds, amiodarone, nefa-
zodone, paracetamol, tolcapone, diclofenac, ximelagatran, troglitazone, perhexiline,
bosentan, entacapone, metformin, and pioglitazone, measurement of resazurin
conversion was done as described by Sison-Young et al.43.
Statistics. Comparisons between two data groups (with n ≥ 3 independent
experiments) were analyzed using an unpaired or paired two-tailed Student’s t-test.
Values of <0.05 were considered significant and are indicated in the graphs as *p <
0.05, **p < 0.01, or ***p < 0.001. All data represent the mean ± SEM (n ≥ 3).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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